Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Paroxysmal Nocturnal Hemoglobinuria Market Landscape Set to Witness Growth at a CAGR of 10% for the Study Period 2018-30 in the 7MM | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

23 Mar, 2021, 17:30 GMT

Share this article

Share toX

Share this article

Share toX

Established SoC, first C5 inhibitors are set to be challenged in the Paroxysmal Nocturnal Hemoglobinuria (PNH) market by second generation C5 inhibitors and novel C3 inhibitors.

LAS VEGAS, March 23, 2021 /PRNewswire/ -- DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Insights, Epidemiology, and Market Forecast' report offers detailed coverage of historical and forecasted epidemiological analysis in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan) for the study period 2018-30. 

The report is created to project true opportunities in the market landscape, help clients form collaborations and agreements that give them a competitive advantage, and plan strategic moves to yield maximum ROI. 

Some of the crucial highlights from the Paroxysmal Nocturnal Hemoglobinuria Market report: 

  • The total PNH prevalent cases in the 7MM were estimated to be 8,385 in 2020 and is expected to increase owing to various factors during the forecasted period.
  • The only disease-modifying therapies in the PNH therapy market are complement inhibition therapy (Alexion Pharmaceuticals' Eculizumab and Ravulizumab) and bone marrow transplantation. 
  • Eculizumab has managed to reduce hemolysis, decrease the number of the required number of transfusions, as well as reducing the rate of thrombosis.
  • Alexion developed another eculizumab-like monoclonal antibody, Ravulizumab, however, is more convenient to administer and has an effective dosing schedule than Eculizumab, thus, is expected to add to the company's revenue. . 
  • The present PNH emerging market consists of second-generation C5 Inhibitors, C3 inhibitors, factor D and Factor B inhibitors. 
  • Key pharmaceutical companies operating in the Paroxysmal Nocturnal Hemoglobinuria therapeutics market are Apellis Pharmaceuticals, Hoffmann-La Roche, Novartis, Alexion Pharmaceutical, Regeneron Pharmaceuticals, RA Pharmaceuticals and others. 
  • The total PNH market size, as per DelveInsght's market analysis, was found to be USD 358.04 million in 7MM in 2020. In the 7MM, the US accounted for approximately 63% of the overall market size of PNH in 2020. 
  • A number of emerging therapies comprising mAb–derived compounds, siRNA, C3 inhibitors, Factor B and D inhibitors are currently in the PNH pipeline.
  • The Paroxysmal Nocturnal Hemoglobinuria market has several unmet needs such as hemolysis, anemia, transfusions, and severe fatigue that might affect bone marrow function, which need to be addressed. 
  • Further, the launch of self-administered therapies in the Paroxysmal Nocturnal Hemoglobinuria therapy market is expected to lower down the treatment burden. 

Want to know more? Get comprehensive insights @ Paroxysmal Nocturnal Hemoglobinuria Market Landscape, Epidemiological Insights, and Pipeline Therapies 

The Paroxysmal Nocturnal Hemoglobinuria market report offers available therapies, treatment landscape, emerging therapies, changing market landscape, individual market share of pipeline therapies, PNH market drivers, and market barriers, PNH market size during the study period 2018-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Paroxysmal Nocturnal Hemoglobinuria is a rare acquired disorder of the pluripotent hematopoietic stem cell; therefore, it can affect erythrocytes, leukocytes, thrombocytes, and probably some endothelial cells. Paroxysmal Nocturnal Hemoglobinuria diagnosis is made based on clinical evaluation, patient history, and several tests that are specialized to identify Paroxysmal Nocturnal Hemoglobinuria cells such as flow cytometry. 

Paroxysmal Nocturnal Hemoglobinuria symptoms often include fatigue, difficulty in swallowing (dysphagia), shortness of breath (dyspnea), pain in the abdomen, anemia, erectile dysfunction, and dark-colored urine (hemoglobinuria). However, hemolysis in Paroxysmal Nocturnal Hemoglobinuria that leads to thrombosis remains to be the most devastating consequence of the blood disorder and can often prove to be fatal. 

 Paroxysmal Nocturnal Hemoglobinuria Epidemiological Analysis & Forecast

Paroxysmal Nocturnal Hemoglobinuria is an ultra-rare blood disorder, and DelveInsight's 7MM Paroxysmal Nocturnal Hemoglobinuria epidemiological analysis demonstrates that it is primarily more common in females than males. Further, the US accounted for the highest diagnosed prevalent cases, approximately 51% of the total cases in the 7MM, followed by Germany. 

The PNH market analysis report proffers historical as well as forecasted epidemiological segmentation for the study period 2018-30: 

  • Total diagnosed Paroxysmal Nocturnal Hemoglobinuria prevalent cases 
  • Gender-specific Paroxysmal Nocturnal Hemoglobinuria cases 

Dive deeper for rich insights into Paroxysmal Nocturnal Hemoglobinuria Epidemiological Analysis 

Paroxysmal Nocturnal Hemoglobinuria Treatment Landscape 

Before the approval of anti-C5 agent-Eculizumab, Paroxysmal Nocturnal Hemoglobinuria was a devastating disease that would lead to breaking of red blood cells prematurely. However, Eculizumab transformed the Paroxysmal Nocturnal Hemoglobinuria treatment landscape. The therapeutic agent not only helped in the management of hemolysis, but also helped in reducing the rate of thrombosis and the number of transfusions. It managed to push bone marrow transplantation to second-line therapy for hemolytic PNH in countries where the drug is available. 

Visit to know more about Paroxysmal Nocturnal Hemoglobinuria Marketed Drugs 

Paroxysmal Nocturnal Hemoglobinuria Market 

The Paroxysmal Nocturnal Hemoglobinuria market is experiencing an influx of several pharmaceutical companies investigating numerous second-generation C5 inhibitors to bridge the treatment gap. Key pharmaceutical players such as Apellis Pharmaceuticals, Hoffmann-La Roche, Novartis, Alexion Pharmaceutical, Regeneron Pharmaceuticals, RA Pharmaceuticals and several others are energetically operating in the domain. 

The PNH pipeline therapies involve second-generation C5 Inhibitors, C3 inhibitors, factor D and Factor B inhibitors expected to get launched in the coming decade and revolutionize the Paroxysmal Nocturnal Hemoglobinuria market owing to the option of self-administration that shall significantly lower down the treatment burden. However, there is a need for clinical trials that study the efficiency of emerging therapies in multicentric versus reference laboratory settings. 

There are several unmet needs in the PNH market in the form of the availability of limited treatment options, high rates of morbidity in PNH patients, and a lack of well-defined protocols to manage the disorder. Moreover, the rarity of the disorder also causes unawareness among the physicians and people regarding Paroxysmal Nocturnal Hemoglobinuria symptoms, treatment and diagnosis. 

Interested in knowing more? Drop by @ Paroxysmal Nocturnal Hemoglobinuria Market Domain and Key Companies

Nevertheless, the studies demonstrated that terminal complement blockade offers a safe and effective treatment option to PNH patients. The Paroxysmal Nocturnal Hemoglobinuria drug pipeline involves several alternative therapies with convenient RoA that have increased half-life which reduces the dose-burden and improved the quality of life. Better diagnosis modalities for such rare diseases are as important as their treatments. Better diagnostics methods over the past decade undoubtedly have lowered down the PNH treatment burden. 

 Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapies 

  • Pegcetacoplan (APL-2): Apellis Pharmaceuticals
  • Crovalimab: Hoffmann-La Roche 
  • Iptacopan or LNP023: Novartis
  • ALXN2040 (or Danicopan): Alexion Pharmaceutical
  • Pozelimab: Regeneron Pharmaceuticals
  • RA101495: UCB Pharma/RA Pharmaceuticals

Know more about the pipeline therapies @ PNH Emerging Drug Therapies 

Scope of the Report 

Coverage: 7MM (the US, EU5, and Japan)

Study Period: 2018-30

Key Companies: Apellis Pharmaceuticals, Hoffmann-La Roche, Novartis, Alexion Pharmaceutical, Regeneron Pharmaceuticals, RA Pharmaceuticals and several others.

Key Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapies: Pegcetacoplan (APL-2), Crovalimab, Iptacopan or LNP023, ALXN2040 (or Danicopan), Pozelimab, RA101495, and others. 

Paroxysmal Nocturnal Hemoglobinuria Market Segmentation: By Geography, By Paroxysmal Nocturnal Hemoglobinuria Therapies

Analysis: Comparative and conjoint analysis of Paroxysmal Nocturnal Hemoglobinuria emerging therapies

Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL's Views

Analyst's Views

Get in touch to know more about the report scope @ PNH Market Landscape and Future Trends 

Table of Contents

1

Key Insights

2

Report Introduction

3

Competitive Intelligence Analysis for Paroxysmal Nocturnal Hemoglobinuria

4

Paroxysmal Nocturnal Hemoglobinuria Market Overview at a Glance

5

Executive Summary of Paroxysmal Nocturnal Hemoglobinuria

6

PNH Epidemiology and Market Methodology

7

Paroxysmal Nocturnal Hemoglobinuria Epidemiology and Patient Population

8

PNH Patient Journey

9

Treatment Algorithm, Current Treatment, and Medical Practices

10

Key Endpoints in PNH Clinical Trials

11

PNH Marketed Therapies 

12

Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies

13

Paroxysmal Nocturnal Hemoglobinuria: 7 Major Market Analysis

14

Attribute analysis

15

Access and Reimbursement Overview of Paroxysmal Nocturnal Hemoglobinuria

16

KOL Reviews

17

Case Reports

18

Paroxysmal Nocturnal Hemoglobinuria Market Drivers

19

PNH Market Barriers

20

SWOT Analysis

21

Disclaimer

21

DelveInsight Capabilities

22

About DelveInsight

Know more about the report offerings @ Paroxysmal Nocturnal Hemoglobinuria Market 

Related Reports 

Hemophilia B Market

Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as UniQure Biopharma B.V./ CSL Behring, Pfizer/Spark Therapeutics, Genzyme (Sanofi Company/ Alnylam Pharmaceuticals), Novo Nordisk, UniQure Biopharma B.V., ApcinteX, Freeline Therapeutics, Sangamo Therapeutics and several others. 

Wilson Disease Market

Get comprehensive historical and forecast analysis of Wilson Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Vivet Therapeutics, Cuprior, GMP-Orphan SAS and Alexion, and several others. 

Eosinophilic Esophagitis Market

Get comprehensive historical and forecast analysis of Eosinophilic Esophagitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Shire, Dr. Falk GmBH, Adare Pharmaceuticals, and Regeneron.

Von Willebrand Disease Market

Get comprehensive historical and forecast analysis of Von Willebrand Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Shire Plc. (earlier Baxalta), CSL Behring, LFB Biomedicaments SA, Octapharma AG, Grifols SA, and others. 

Familial Chylomicronemia Syndrome Market

Get comprehensive historical and forecast analysis of Familial Chylomicronemia Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Akcea Therapeutics/Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Amryt Pharma, and others. 

Adrenoleukodystrophy Market

Get comprehensive historical and forecast analysis of Adrenoleukodystrophy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Bluebird Bio, Minoryx Therapeutics, Magenta Therapeutics, and others. 

Lamellar Ichthyosis Market

Get comprehensive historical and forecast analysis of the Lamellar Ichthyosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Galderma, Mayne, Pharma, Krystal Biotech, Timber Pharmaceuticals, and others. 

Pulmonary Arterial Hypertension Market

Get comprehensive historical and forecast analysis of the Lamellar Ichthyosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as United Therapeutics, Arena Pharmaceuticals, Altavant Sciences, Acceleron Pharma, Actelion Pharmaceuticals, and others. 

Duchenne Muscular Dystrophy Market

Get comprehensive historical and forecast analysis of the Duchenne Muscular Dystrophy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Sarepta Therapeutics, FibroGen, Capricor, Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco, and others. 

Warm Autoimmune Hemolytic Anemia Market

Get comprehensive historical and forecast analysis of the Duchenne Muscular Dystrophy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Rigel Pharmaceuticals, Apellis Pharmaceuticals, Momenta Pharmaceuticals, Alexion, Immunovant, and others.

Get in touch with our Business Executive @ Rare disease market insights to know more. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.